-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651A.O1.6 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, Translational Research, Bispecific Antibody Therapy, elderly, genomics, Plasma Cell Disorders, Combination therapy, drug development, immune mechanism, Diseases, Therapies, immunology, Immunotherapy, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease
Monday, December 12, 2022: 2:45 PM-4:15 PM
Hall E (Ernest N. Morial Convention Center)
Moderators:
Jonathan J Keats, PhD, Translational Genomics Research Institute and Benjamin Diamond, University of Miami, Sylvester Comprehensive Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
2:45 PM

Sophia Adamia, PhD1,2, Daisuke Ogiya, MD, PhD3*, Evdoxia Hatjiharissi4*, Michael P. Chu, MD5, Zuzana Chyra6,7*, Kenneth Wen8*, Yu-Tzu Tai, PhD9,10, David M. Dorfman, MD, PhD11,12, Teru Hideshima, MD, PhD9,13 and Kenneth C. Anderson, MD1,9,14

1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Institute of Medical and Public Health Research, Ilia State University, Tbilisi, Georgia
3Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
4First Department of Internal Medicine, Division of Haematology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
5Department of Oncology, Cross Cancer Institute, Edmonton, AB, Canada
6Department of Hematooncology, University Hospital of Ostrava; Masaryk University, Ostrava, Czech Republic
7Department of Internal Studies, University of Ostrava, Ostrava, Czech Republic
8Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
9Harvard Medical School, Boston, MA
10The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
11Department of Pathology, Brigham and Women's Hospital, Boston, MA
12Harvard Medical School, Boston
13Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
14Dana-Farber Cancer Institute, Boston, MA

3:00 PM

Simon Steiger1,2,3*, Raphael Lutz, MD2,4,5*, Nina Prokoph, PhD2,6*, Subarna Palit, PhD7,8*, Stephan M Tirier, PhD1*, Philipp Reichert, PhD2*, Anja Baumann6*, Nadine Hefner, MSc2*, Sabrina Schumacher1*, Dominik Vonficht, MSc3,4,5*, Florian Grünschläger, MSc3,4,5*, Alexandra M Poos, PhD2,6*, Lukas John, MD2,6*, Laleh Haghverdi, PhD8*, Jan-Philipp Mallm, PhD1,9*, Elias K Mai, MD2*, Mirco Friedrich2,10*, Katharina Kriegsmann, MD2*, Mohamed H.S. Awwad, PhD2*, Anna Jauch, PhD11*, Uta Bertsch, MD2,12*, Diana Tichy, PhD13*, Carsten Müller-Tidow, MD2,12*, Roland Schroers, MD14*, Hans Salwender, M.D.15*, Britta Besemer, MD16*, Roland Fenk, MD17*, Katja C. Weisel, MD18, Hartmut Goldschmidt, MD2,12, Stefanie Huhn, PhD2*, Michael Hundemer, MD2*, Karsten Rippe, PhD1*, Simon Haas, PhD4,7,8,19,20*, Niels Weinhold, PhD2* and Marc S Raab, MD2,6*

1Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
2Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
3Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
4Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
5Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
6Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
7Berlin Institute of Health (BIH), Charité – Universitätsmedizin Berlin, Berlin, Germany
8Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center in the Helmholtz Association, Berlin, Germany
9Single Cell Open Lab, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
10German Cancer Research Center (DKFZ), Heidelberg, Germany
11Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany
12National Center for Tumor Diseases (NCT), Heidelberg, Germany
13Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
14Medizinische Universitätsklinik Ruhr-Universität-Bochum, Knappschaftskrankenhaus, Bochum, Germany
15Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany
16Medical Clinic II, University Tuebingen, Tuebingen, Germany
17Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany
18Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
19Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
20German Cancer Consortium (DKTK), Heidelberg, Germany

3:15 PM

Shuichiro Takahashi1*, Simone A Minnie, PhD1*, Samuel RW Legg1*, Christine R Schmidt1*, Kathleen S Ensbey1*, Damian J. Green, MD2,3 and Geoffrey R Hill, MD1,3

1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
3Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

3:30 PM

Bachisio Ziccheddu, PhD1*, Benjamin Diamond, MD2, Kylee H Maclachlan, MBBCh, PhD3, Justin Taylor, MD4, Eileen M Boyle, MD, MSc5, Juan E. Arango Ossa6*, Jahn Jacob2*, Maurizio Affer2*, Tulasigeri M Totiger, PhD2*, David Coffey, MD1, Justin Watts, MD7, Sydney X. Lu, MD, PhD8, Niccolo Bolli, MD9,10, Kelly L Bolton, MD11, Jae H Park, MD12, Heather Landau, MD13, Karuna Ganesh, MBBChir, MA, PhD14*, Andrew McPherson15*, Mikkael A. Sekeres, MD4, Alexander M Lesokhin, MD3, David J. Chung, MD, PhD13, Yanming Zhang, MD16, Caleb Ho, MD16, Mikhail Roshal, MD17, Jeffrey W. Tyner18, Stephen D Nimer, MD19, Elli Papaemmanuil, PhD20, Saad Usmani, MD21, Gareth J. Morgan, MD5, Ola Landgren, MD22 and Francesco Maura, MD2

1Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
2Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami
3Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
5Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York
7Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL
8Division of Hematology, Dept. of Medicine, Stanford University, Stanford, CA
9Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
10Hematology & BMT Unit, Fondazione IRCCS Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy
11Department of Medicine, Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine, Saint Louis, MO, Washington University In St Louis, St Louis, MO
12Memorial Sloan-Kettering Cancer Ctr., New York, NY
13Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
14Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
15Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
16Department of Pathology, Memorial Sloan Kettering Cancer Center, New York
17Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
18Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
19Sylvester Comprehensive Cancer Center, University of Miami, Miami
20Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
21Myeloma Service, Memorial Sloan Kettering Cancer Center, New York
22Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

3:45 PM

Jan Eckmann1*, Tanja Fauti, PhD2*, Aintzane Zabaleta, PhD3*, Laura Blanco3*, Sahar Kassem4*, Nadege Carrié4*, Stefan Lorenz1*, Alejandro Carpy1*, Tony Christopeit1*, Georg Fertig1*, Luise Bernasconi5*, Marlene Biehl2*, Sarah Diggelmann2*, Melanie Knobloch2*, Maud Mayoux6*, Charles Dumontet7*, Bruno Paiva3*, Ludovic Martinet4*, Stéphane Leclair1*, Wei Xu2*, Christian Klein, PhD8 and Pablo Umaña2

1Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany
2Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland
3University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Pamplona, Spain
4Centre De Rechecrche En Cancérologie De Toulouse De Inserm U1037, Toulouse, France
5Lonza, Bern, Switzerland
6University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland
7University of Lyon/Hospices Civils de Lyon, Cancer Research Center of Lyon (CRCL), Pierre-Bénite Cedex, France
8Roche Innovation Center Zurich, Schlieren, Switzerland

4:00 PM

Paola Neri, MD, PhD1, Sungwoo Ahn, PhD1*, Holly Lee, MD1, Noemie Leblay, PhD1*, Mirco Friedrich2*, Ranjan Maity, PhD1*, Rémi Tilmont, MD1*, Elie Barakat, MSc1*, Marc S Raab, MD2* and Nizar Jacques Bahlis, MD1

1Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
2German Cancer Research Center, Heidelberg, Germany

*signifies non-member of ASH